ProCE Banner Activity

177Lu-DOTATATE vs Sunitinib as Initial Treatment for Advanced Grade 2 Pancreatic Neuroendocrine Tumors Using Matching-Adjusted Indirect Comparison

Conference Coverage
Slideset

Matching-adjusted indirect comparison suggested that 177Lu-DOTATATE plus long-acting octreotide results in longer progression-free survival than sunitinib as a first-line therapy for advanced grade 2 pancreatic neuroendocrine tumors.

Released: February 05, 2025

Expiration: August 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation